1.05

0.00% 0.00

Tiziana Life Sciences Ltd (TLSA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.05

Aprire:

$1.08

Volume 24 ore:

553.40K

Relative Volume:

0.84

Capitalizzazione di mercato:

$133.62M

Reddito:

Utile/perdita netta:

$-18.43M

Rapporto P/E:

-6.7394

EPS:

-0.1558

Flusso di cassa netto:

$-12.87M

1 W Prestazione:

-11.76%

1M Prestazione:

+36.35%

6M Prestazione:

-21.64%

1 anno Prestazione:

-48.02%

Intervallo 1D:

$1.03

$1.10

Intervallo di 1 settimana:

$1.02

$1.20

Portata 52W:

$0.7615

$2.15

Tiziana Life Sciences Ltd Stock (TLSA) Company Profile

Nome

Tiziana Life Sciences Ltd

Settore

Healthcare (1052)

Industria

Biotechnology (594)

Telefono

Indirizzo

Dipendente

Cinguettio

@tizianals

Prossima data di guadagno

null

Ultimi documenti SEC

TLSA's Discussions on Twitter

Compare TLSA vs VRTX, MRNA, REGN, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TLSA Tiziana Life Sciences Ltd	1.05	133.62M	0	-18.43M	-12.87M	-0.1558
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-09-03	Iniziato	BTIG Research	Buy
2020-12-22	Iniziato	B. Riley Securities	Buy
2018-12-17	Iniziato	Laidlaw	Buy

Tiziana Life Sciences Ltd Borsa (TLSA) Ultime notizie

Sep 30, 2026

A rare disorder’s median survival is 6–9 years. Tiziana seeks FDA rare-disease designation for its nasal drug. - Stock Titan

Sep 30, 2026

Form 4 Tiziana Life Sciences Ltd For: 30 September By Investing.com - Investing.com Canada

Sep 30, 2026

Form 4 Tiziana Life Sciences Ltd For: 30 September By Investing.com - Investing.com UK

Sep 30, 2026

Sep 22, 2026

TLSA Reiterated by BTIG -- Price Target Maintained at $7.00 - GuruFocus

Sep 22, 2026

Sep 17, 2026

Tiziana Life Sciences (NASDAQ: TLSA) Enters MOU to Launch RRMS Combination Therapy Trial - Kalkine Media

Sep 17, 2026

Tiziana (TLSA) lines up MS trial for patients failing current drugs with a nasal antibody twist. - Stock Titan

Sep 17, 2026

A planned MS trial will test Tiziana’s nasal drug with existing treatment - Stock Titan

Sep 17, 2026

Sep 09, 2026

ADAG Stock Price, Quote & News - Syfe

Sep 09, 2026

Sep 08, 2026

TLSA: Tiziana Life Sciences Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 08, 2026

Sep 03, 2026

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration - Yahoo Finance

Sep 03, 2026

Small cap wrap: Tiziana Life Sciences, Thistle Resources, Alvopetro, BioHarvest... - Proactive financial news

Sep 03, 2026

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration - Proactive financial news

Sep 03, 2026

Tiziana Life Sciences initiated with a Buy at BTIG - TipRanks

Sep 03, 2026

Tiziana Life Sciences initiated with a Buy at BTIG - TipRanks

Sep 03, 2026

This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Sep 03, 2026

TLSA Initiated Coverage by BTIG -- Price Target Set at $7.00 - GuruFocus

Sep 03, 2026

BTIG Initiates Tiziana Life Sciences at Buy With $7 Price Target - marketscreener.com

Sep 03, 2026

BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com India

Sep 03, 2026

BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com

Sep 03, 2026

BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com UK

Sep 03, 2026

Small cap wrap: Tiziana Life Sciences, Thistle Resources, Alvopetro, BioHarvest... - Proactive financial news

Sep 03, 2026

Aug 24, 2026

Wall Street ends on a mixed note as Dow gains despite semiconductor slump - proactiveinvestors.com.au

Aug 24, 2026

Market movers: Strategy, Bitmine, Tiziana Life Sciences... - Proactive Investors

Aug 24, 2026

Tiziana (NASDAQ: TLSA) highlights intranasal ALS trial and MS data - Stock Titan

Aug 24, 2026

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 - kommunikasjon.ntb.no

Aug 24, 2026

Tiziana Life Sciences Ltd. - Via Ritzau

Aug 24, 2026

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026 - Yahoo Finance

Aug 24, 2026

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 - The Manila Times

Aug 24, 2026

Aug 11, 2026